|1.||Maeda, Hiroshi: 7 articles (07/2015 - 01/2005)|
|2.||Yao, Yang: 6 articles (01/2015 - 04/2010)|
|3.||Greish, Khaled: 5 articles (07/2015 - 01/2005)|
|4.||Shen, Zan: 5 articles (01/2015 - 06/2012)|
|5.||Daruwalla, Jurstine: 4 articles (07/2015 - 08/2007)|
|6.||Malcontenti-Wilson, Cathy: 4 articles (07/2015 - 08/2007)|
|7.||Christophi, Chris: 4 articles (07/2015 - 08/2007)|
|8.||Fang, Jun: 4 articles (02/2015 - 01/2005)|
|9.||Lin, Feng: 4 articles (01/2015 - 04/2010)|
|10.||Salerno, Milena: 4 articles (11/2014 - 02/2009)|
01/01/2015 - "Pirarubicin (THP) is a newer generation anthracycline anticancer drug with antineoplastic efficacy against numerous tumors. "
08/01/2012 - "To analyze the influence of intravesical Pirarubicin (THP) instillation on the prediction results of European Organization for Research and Treatment of Cancer (EORTC) risk tables and to discuss the efficacy of EORTC risk tables in clinical application. "
11/01/2013 - "This study conducted further analysis of the Pirarubicin Monotherapy Study Group cohort, focusing on intravesical seeding of cancer cells. "
11/15/1990 - "A Phase I study of intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin (Pirarubicin) was done in 55 patients in good performance status with refractory tumors. "
07/01/2015 - "SMA-pirarubicin (100 mg/kg) induced ROS exclusively in tumors with minimal levels in serum and cardiac tissue. "
|2.||Breast Neoplasms (Breast Cancer)
01/01/1990 - "This three-drug combination containing pirarubicin is effective in treating metastatic breast cancer, with less severe toxicity than other anthracycline-containing combinations."
01/01/1991 - "A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients."
06/01/1990 - "Thirty-four patients with metastatic breast cancer were treated in a multicenter phase II study with pirarubicin (THP) using a dosage of 75 mg/m2/every 3 weeks. "
06/01/1990 - "Phase II study of pirarubicin in metastatic breast cancer."
05/01/1990 - "In summary, the early results of this trial suggest that pirarubicin is an active and rather well tolerated drug in pretreated patients with advanced breast cancer."
|3.||Urinary Bladder Neoplasms (Bladder Cancer)
08/01/2014 - "We also found that a single early dose of pirarubicin following transurethral resection of bladder tumor improved MMC efficacy in the high-dose group. "
01/01/2013 - "Efficacy of immediate instillation combined with regular instillations of pirarubicin for Ta and T1 transitional cell bladder cancer after transurethral resection: a prospective, randomized, multicenter study."
05/01/2015 - "This study aimed to investigate the role of autophagy in pirarubicin-treated bladder cancer cells. "
08/01/2012 - "In vitro and in vivo studies of pirarubicin-loaded SWNT for the treatment of bladder cancer."
11/01/1992 - "Phase II trial of pirarubicin in the treatment of advanced bladder cancer."
11/01/2010 - "Improved detection of nonmuscle invasive urothelial carcinoma of the bladder using pirarubicin endoscopy: a prospective, single-center preliminary study."
05/01/2004 - "washing with pirarubicin cured 2-day-old, but not 7-day-old, peritoneal carcinomatosis in rats. "
09/15/1992 - "Phase II trial of 4'-0-tetrahydropyranyladriamycin (pirarubicin) in head and neck carcinoma."
01/01/1986 - "An oriented phase II trial of THP-adriamycin in breast carcinoma."
01/01/1994 - "We conclude that Pirarubicin used with this dosage and schedule has no activity in advanced pancreatic carcinoma."
|5.||Osteosarcoma (Osteogenic Sarcoma)
06/01/2012 - "Pirarubicin (THP) is recently found to be effective in treating patients with advanced, relapsed or recurrent high-grade osteosarcoma. "
06/01/2013 - "Further studies, especially prospective clinical trials, focusing on pirarubicin-based treatments for relapsed and refractory osteosarcoma patients should be strongly considered."
01/01/2015 - "Se-MSC inhibited the proliferation of the drug-resistant osteosarcoma cell line Saos-2/MTX300 and enhanced the inhibitory effect of pirarubicin on MG63 cells. "
06/01/2012 - "Pirarubicin inhibits multidrug-resistant osteosarcoma cell proliferation through induction of G2/M phase cell cycle arrest."
12/01/2014 - "The aim of this study was to investigate the combined inhibitory effect of LY294002 and pirarubicin on human osteosarcoma (OS) cells in vitro. "
|10.||Etoposide (VP 16)
|1.||Drug Therapy (Chemotherapy)
|3.||Combination Drug Therapy (Combination Chemotherapy)